Navigation Links
iBio, Inc. Prices $4.2 Million Public Offering

NEWARK, Del., April 23, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) announced today the pricing of an underwritten public offering of 8,925,000 units at $0.48 per unit for gross proceeds of approximately $4,280,000. Each unit consists of one share of common stock and 0.40 of a warrant to purchase one share of common stock. The warrants will have an exercise price of $0.53 per share, will be exercisable from the date of issuance and will expire on the third anniversary of the issuance date. The offering is being made pursuant to an effective registration statement under the Securities Act of 1933, as amended.

(Logo: )

iBio plans to use proceeds of the offering for working capital, including further development of iBio's product candidates and proprietary technology, business development and for other general corporate purposes. 

Roth Capital Partners is acting as sole manager for the offering. iBio expects to close the transaction, subject to customary conditions, on or about April 26, 2013.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering will be made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from:

Roth Capital Partners
By Email:
By Fax: 949.720.7227
Or by mail:
888 San Clemente Drive
Newport Beach, CA 92660
ATTN: Equity Capital Markets

SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. iBio, Inc. Submits Plan to Satisfy NYSE Amex Continued Listing Standards
2. iBio, Inc. Prices $10 Million Public Offering
3. iBio, Inc. and GE Healthcare form new global alliance
4. iBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards
5. iBio, Inc. Receives Anticipated Notice from NYSE MKT that Company is Below Certain Continued Listing Standards
6. iBio, Inc. Announces Proposed Public Offering
7. BioMed Realty, L.P. Prices $250 Million Offering Of 4.25% Senior Unsecured Notes Due 2022
8. Sequenom Prices Offering of $110 Million of its 5.00% Convertible Senior Notes Due 2017
9. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Show Healthcare Payers Aren’t Taking Drug Prices Laying Down
10. BioMed Realty Trust Prices Public Offering Of 12,700,000 Shares Of Common Stock
11. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
Post Your Comments:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology:
(Date:10/4/2017)... 4, 2017  GCE Solutions, a global clinical research organization (CRO), ... anonymization solution on October 4, 2017. Shadow is designed to assist ... with policy 0070 of the European Medicines Agency (EMA) in meeting ... ... ...
(Date:6/30/2017)... 30, 2017 Today, American Trucking Associations ... of face and eye tracking software, became the ... program. "Artificial intelligence and advanced ... monitor a driver,s attentiveness levels while on the ... to detect fatigue and prevent potential accidents, which ...
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
Breaking Biology News(10 mins):